-
Your selected country is
Middle East / Africa
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Fluorescent two-color dot plot of CD180 expression on human peripheral blood monocyte-derived dendritic cells. Human dendritic cells were costained with PE Mouse Anti-Human CD180 (Cat. No. 551953) and FITC Mouse Anti-Human CD209 (Cat. No. 561764/ 551264). The two-color dot plot was derived from gated events with the side and forward light-scattering characteristics of viable dendritic cells.
BD Pharmingen™ PE Mouse Anti-Human CD180
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
The G28-8 monoclonal antibody specifically recognizes RP105/Bgp95, a 95-105 kDa type I membrane protein consisting of extracellular leucine-rich repeats and a short cytoplasmic domain. It is expressed on mantle zone B cells, but weakly on germinal center B cells. RP105/Bgp95 is also expressed on peripheral blood monocytes, dendritic cells, and a subset of peripheral blood lymphocytes. The extracellular domain associates with a molecule called MD-1 to form a cell surface receptor complex RP105/Bgp95/MD- 1. This receptor belongs to the family of toll-like receptors (TLR). Studies show that RP105/Bgp95/MD-1, working in concert with TLR4, controls B cell recognition and signaling of lipopolysaccharide (LPS). Reports on functional studies show that G28-8 monoclonal antibody can induce a G0 to G1 cell cycle transition and was synergistic with PMA, anti-µ, or anti-CD40 in inducing proliferation of resting B cells.
Development References (5)
-
Fugier-Vivier I, de Bouteiller O, Guret C. Molecular cloning of human RP105. Eur J Immunol. 1997; 27(7):1824-1827. (Biology). View Reference
-
Mason D. David Mason .. et al., ed. Leucocyte typing VII : white cell differentiation antigens : proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. Oxford: Oxford University Press; 2002.
-
Ogata H, Su I, Miyake K, et al. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med. 2000; 192(1):23-29. (Biology). View Reference
-
Roshak AK, Anderson KM, Holmes SD. Anti-human RP105 sera induces lymphocyte proliferation. J Leukoc Biol. 1999; 65(1):43-49. (Biology). View Reference
-
Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA. Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 1988; 140(12):4071-4078. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.